RxDoctor Payments Data

Megan Webb, PA

Physician Assistant · Brookline, MANPI 1679607774

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 629 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,502in general payments, 2019–2025

Across 629 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Amgen$2K
  • Incyte Corporation$1K
  • Johnson & Johnson$1K
  • Novartis$919
  • Lilly USA, LLC$858
  • plus $6K from 23 others

What the payments were for

  • Food & beverage$14,12297%
  • Education$3803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,502 in reported general payments places this provider in the 95th percentile of 3,507 physician assistant providers in Massachusetts.

See all physician assistant providers in Massachusetts

Medicare billing

Part B allowed, 2024
$262,162
Medicare patients
660
Services billed
5,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab18$156,861
OtezlaApremilast20$107,354
Dupixent PenDupilumab22$99,372
EucrisaCrisaborole11$8,690
Fluorouracil33$2,143
Ketoconazole139$2,046
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc76$1,918
Metronidazole56$1,832
Betamethasone Valerate54$1,430
Clobetasol Propionate24$1,190
Sulfacetamide Sodium12$1,173
Levocetirizine Dihydrochloride59$1,052
Triamcinolone Acetonide110$1,013
Clindamycin Phosphate45$978
ErythromycinErythromycin Base In Ethanol14$843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,551$107,35420 claims
PfizerEucrisa$513$8,69011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,507 physician assistant providers in Massachusetts.

Other physician assistant in Brookline

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →